Abstract / Description of output
Amongst 200 patients developing HAP outwith the ICU, 61% were treated empirically without broad-spectrum gram-negative coverage, with clinical cure in 69.7%. Lower disease severity markers(SIRS, hypoxia, tachypnoea, neutrophilia) and absence of diabetes mellitus and prior doxycycline treatment (but not time to HAP onset) identified patients not requiring broad-spectrum gram-negative coverage.
Original language | English |
---|---|
Journal | Clinical Infectious Diseases |
Early online date | 8 Apr 2020 |
DOIs | |
Publication status | E-pub ahead of print - 8 Apr 2020 |